Cite
HARVARD Citation
Merrill, J. et al. (n.d.). 98 Results of a phase 2, double-blind, randomized, placebo-controlled study of a reversible B cell inhibitor, XmAb®5871, in systemic lupus erythematosus (SLE). Lupus science & medicine. pp. A73-A74. [Online].